Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) CFO Gordon Dunn Buys 122,221 Shares

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) CFO Gordon Dunn bought 122,221 shares of Quoin Pharmaceuticals stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $0.45 per share, for a total transaction of $54,999.45. Following the purchase, the chief financial officer now directly owns 151,077 shares in the company, valued at approximately $67,984.65. The trade was a 423.55 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Quoin Pharmaceuticals Trading Down 1.6 %

Shares of QNRX traded down $0.01 on Friday, reaching $0.55. 553,804 shares of the company’s stock were exchanged, compared to its average volume of 1,118,553. Quoin Pharmaceuticals, Ltd. has a 12 month low of $0.43 and a 12 month high of $6.18. The stock has a market capitalization of $2.78 million, a P/E ratio of -0.14 and a beta of 1.79. The business has a 50 day moving average price of $0.68 and a two-hundred day moving average price of $0.63.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.